KISS = Kinase Inhibition With Sprycel Start up [New Zealand]

What is the purpose of the study

This study will assess the efficacy and safety of a treatment plan for patients with newly diagnosed CML-CP. In the first study stage, patients will be given dasatinib (Sprycel) to more rapidly induce a molecular response (MR3.0). At 13 months, patients will be switched to imatinib to maintain CML in that remission.
Patients who do not achieve confirmed MR3.0 at 13 months will not be eligible to switch to imatinib treatment and will continue on dasatinib treatment.

Key inclusion criteria

This study includes male or female patients who:

– are at least 18 years old
– have an Eastern Co-Operative Oncology Group (ECOG) status of 0, 1 or 2
– have been diagnosed with chronic myeloid leukemia in chronic phase within 3 months of enrolment
– have cytogenetic or molecular confirmation of Philadelphia chromosome (Ph+) or variants of (9;22) translocations

Key exclusion criteria

Estimated primary completion date

Where can I find additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

New Zealand

Auckland City Hospital
Auckland
Principal Investigator: Prof Peter Browett

Middlemore Hospital
Auckland
Principal Investigator: Dr Gordon Royle

Christchurch Hospital
Christchurch
Principal Investigator: Dr Emma Jane McDonald

Dunedin Hospital
Dunedin
Principal Investigator: Dr Lucy Pemberton

Waikato Hospital
Hamilton
Principal Investigator: Humphrey Pullon

Taranaki Base Hospital
New Plymouth
Principal Investigator: Bart Baker

Palmerston North Hospital
Palmerston North
Principal Investigator: Bart Baker

North Shore Hospital
Takapuna
Principal Investigator: Henry Chan

Wellington Hospital
Wellington
Principal Investigator: Victoria Campion